ライフサイエンスコーパス: serum bilirubin

1 efore, it is an important candidate gene for serum bilirubin.

2 ound most portal veins, with no elevation of serum bilirubin.

3 d to an increase in the free fraction of his serum bilirubin.

4 jaundice due to an increase in unconjugated serum bilirubin.

5 imated glomerular filtration rate, and total serum bilirubin.

6 ociated with a greater than 25% reduction in serum bilirubin.

7 sk of death included higher than 115 mumol/L serum bilirubin 2-5 days after biliary stenting (HR 3.27

8 ality rises steeply with small increments of serum bilirubin above normal.

9 dose of the virus on day 98 markedly reduced serum bilirubin again.

10 of liver dysfunction such as high levels of serum bilirubin, alkaline phosphatase, alanine transamin

11 Additionally, increased serum bilirubin and alanine aminotransferase levels were

12 were ambulatory with mostly normal levels of serum bilirubin and albumin concentrations.

13 tic cholestasis as seen by decreases in both serum bilirubin and alkaline phosphatase levels in TG mi

14 but not Ad5LacZ, as demonstrated by elevated serum bilirubin and ammonia levels.

15 es population and hour-based norms for total serum bilirubin and assessment of risk factors.

16 R surgery, the following were determined: 1) serum bilirubin and bile acid levels; 2) serum levels of

17 After reperfusion: 1) serum bilirubin and bile acids increased; 2) levels of a

18 An inverse association between serum bilirubin and coronary heart disease has been repo

19 e disease) is calculated on the basis of the serum bilirubin and creatinine concentrations and the in

20 multivariate modeling, elevated pretreatment serum bilirubin and creatinine levels as well as the pre

21 r End-Stage Liver Disease (MELD) consists of serum bilirubin and creatinine levels, International Nor

22 s who received itraconazole developed higher serum bilirubin and creatinine values in the first 20 da

23 Serum bilirubin and other hepatic variables gradually im

24 primary nonfunction identified preoperative serum bilirubin and serum creatinine as significant pred

25 ing toxicities were related to elevations in serum bilirubin and serum creatinine levels.

26 diabetes, hepatitis C status, serum albumin, serum bilirubin and serum creatinine.

27 re correlated with a progressive increase in serum bilirubin and the development of a predominantly l

28 inophen concentration, prothrombin time, and serum bilirubin and transaminase concentrations.

29 At 24 hours after collar implantation, serum bilirubin and vascular, liver, and spleen HO-1 mes

30 17.1 mumol/L (>/=1 mg/dL), normal conjugated serum bilirubin, and no evidence of hepatitis, cholestas

31 cirrhosis related HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender

32 In conclusion, the value of total serum bilirubin at a particular point in time after tran

33 core and HE at admission and the increase in serum bilirubin at day 4 were independent predictors of

34 increased from 53 to 56 years and the median serum bilirubin at transplantation fell from 270 micromo

35 lestasis after BDL was confirmed by baseline serum bilirubin (BDL = 7.34 +/- 0.72 mg/dl, mean +/- SEM

36 splant survival: high serum creatinine, high serum bilirubin, biliary tree malignancy, previous upper

37 , intraoperative hypotension and predonation serum bilirubin, but did not decline with the increased

38 heparin was defined as a reduction in total serum bilirubin by 50% within 10 days of starting treatm

39 ection of Ad-BUGT1, but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pup

40 after infection, but showed no reduction of serum bilirubin by reinjection of the virus on that day.

41 Jaundice was defined as a serum bilirubin concentration > or = 3 mg/dL.

42 The optimal model included the total serum bilirubin concentration, oral intake, need for tre

43 encephalopathy; sustained quadrupling of the serum bilirubin concentration; marked worsening of fatig

44 The observed inverse correlation between serum bilirubin concentrations and a history of nonderma

45 There is an inverse relationship between serum bilirubin concentrations and risk of coronary arte

46 gical malignancy exhibit significantly lower serum bilirubin concentrations compared with those who d

47 ubin-UGT-deficient jaundiced Gunn rats, mean serum bilirubin concentrations decreased by 40%, 60% and

48 zygote UGT1A1*28 allele carriers with higher serum bilirubin concentrations exhibit a strong associat

49 art of conditioning therapy for unconjugated serum bilirubin concentrations of at least 17.1 mumol/L

50 mic effect was observed in group A, in which serum bilirubin concentrations were reduced to 1.7+/-0.4

51 The primary endpoint was the change of serum bilirubin, creatinine and serum BUN levels before

52 , a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was

53 D staging was defined by the extent of rash, serum bilirubin, diarrhea, and confirmatory histology.

54 nts treated with weekly irinotecan, baseline serum bilirubin does not reliably predict overall irinot

55 Mean total serum bilirubin fell from 9.14 +/- 0.01 to a nadir of 1.

56 up to 72 hours of age or a decrease in total serum bilirubin for infants older than 72 hours of age w

57 Serum bilirubin, gamma-glutamyltranspeptidase, and chole

58 mm Hg best predicted PLF defined by peak of serum bilirubin greater than 120 mumol/L and 90-day mort

59 efinitions of PLF: "50-50" criteria, peak of serum bilirubin greater than 120 mumol/L, and grade C PL

60 umption, elevated AST and/or ALT (<300 U/L), serum bilirubin >34 mumol/L, and elevated INR.

61 opathy, variceal bleeding, prothrombin <45%, serum bilirubin >45 mumol/L, albumin <28 g/L, and/or cre

62 -50 criteria" (ie, prothrombin time <50% and serum bilirubin >50 micromol/L on postoperative day 5) a

63 Increased serum bilirubin has been shown to be a negative predicti

64 Serum bilirubin higher than 115 mumol/L 2-5 days after t

65 mparison), even after excluding those with a serum bilirubin higher than 2.0 mg/dL.

66 vanced disease and demonstrated decreases in serum bilirubin, improvement in coagulopathy, and decrea

67 is mostly benign, excessively high levels of serum bilirubin in a small percentage of newborns can ca

68 event was a moderate transient elevation in serum bilirubin in one participant.

69 Mean serum bilirubin in these nine patients was 8.7 mg/dl bef

70 Similarly, serum bilirubin increased by a mean of 0.34 mg/dl in ind

71 After 2 mo serum bilirubin increased gradually.

72 ) status, nutritional status, serum albumin, serum bilirubin, international normalized ratio, and the

73 Serum bilirubin is a potent endogenous antioxidant and h

74 Serum bilirubin is an endogenous antioxidant that is rou

75 In particular, each 1-mg/dL increase in serum bilirubin is associated with a markedly decreased

76 Variation in serum bilirubin is associated with altered cardiovascula

77 antation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count.

78 tes, variceal bleeding, or encephalopathy; a serum bilirubin less than 3 mg/dL; serum albumin 3 g/dL

79 native liver at 24 months of age with total serum bilirubin less than 6 mg/dL (n = 54).

80 therapy, significantly reduced the mean peak serum bilirubin level (7.0 vs. 9.8 mg per deciliter [120

81 Serum bilirubin level decreased significantly in the FPS

82 logic disorder versus solid tumor (P = .06), serum bilirubin level greater than 1.1 mg/dL (P = .08),

83 Serum bilirubin level measured before a statin prescript

84 The median serum bilirubin level of the patients was 21.8 mg/dl, 85

85 The median peak serum bilirubin level through day 20 was 2.6 mg/dL (rang

86 L-1 patients had transient elevations in the serum bilirubin level to > or = 4 mg/dL.

87 The serum bilirubin level was reduced from 7.1 +/- 0.75 mg/d

88 In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduc

89 -/-) mice develop significantly higher total serum bilirubin levels (23.2 +/- 2.3 versus 14.9 +/- 2.1

90 factors (6% vs. 70%; P < .001), higher peak serum bilirubin levels (45% vs. 5% with peak levels > 15

91 575 participants with 2,532 diabetes cases), serum bilirubin levels (total, direct and indirect) incr

92 Serum bilirubin levels also fell from a median of 385 to

93 report an association between neonatal total serum bilirubin levels and childhood asthma.

94 Early postoperative testing of serum bilirubin levels and hepatobiliary scintigraphy ar

95 t support the protective association between serum bilirubin levels and incident T2D in the middle-ag

96 ty of liver disease as assessed via elevated serum bilirubin levels and low levels of serum albumin a

97 ssociated with overall mortality, and higher serum bilirubin levels and stage 4 fibrosis were associa

98 ctional and prospective associations between serum bilirubin levels and T2D risk in the Dongfeng-Tong

99 Serum bilirubin levels are influenced by many factors, b

100 Serum bilirubin levels are significantly higher in men (

101 on of human BUGT1 (hBUGT1) with reduction of serum bilirubin levels by 70%.

102 ntify genetic contributors to variability in serum bilirubin levels by combining results from three g

103 for UGT1A1*28 (genotype 7/7) have increased serum bilirubin levels compared with carriers of the 6 a

104 ubin glucuronides were excreted in bile, and serum bilirubin levels declined by 25-35% in 2-4 weeks a

105 Serum bilirubin levels declined by 30% +/- 4% in 2 weeks

106 Serum bilirubin levels decreased from 7.2 to 1.8 mg/dl w

107 nthetic function or with lower pretransplant serum bilirubin levels fared as well as younger patients

108 glucuronides in bile and a reduction of mean serum bilirubin levels from 7.0 mg/dl to 1.9-2.7 mg/dl w

109 ne expression was shown by reduction of mean serum bilirubin levels from 7.0 mg/dL to 2.3 mg/dL in 14

110 n in the gene encoding the UGT1*1 enzyme and serum bilirubin levels in a Scottish population.

111 velopmental risks associated with high total serum bilirubin levels in newborns are not well defined.

112 Phenobarbital treatment "normalized" serum bilirubin levels in recipients of orthotopic Wista

113 determine the demographics and correlates of serum bilirubin levels in the general population.

114 ar was superior for patients who had maximal serum bilirubin levels in the normal (78%) or minimally

115 that UGT1A1 may be a major gene controlling serum bilirubin levels in the population.

116 phototherapy or exchange transfusion, total serum bilirubin levels in the range included in this stu

117 Serum bilirubin levels increased slightly with each drug

118 In Ad-E3-hBUGT-injected rats, serum bilirubin levels increased to 4.5 mg/dl by 84 days

119 In contrast, rats receiving Ad-hBUGT had serum bilirubin levels of 7 mg/dl on day 84 after infect

120 e identified 140 infants with neonatal total serum bilirubin levels of at least 25 mg per deciliter (

121 tive than the wild-type six repeats, and the serum bilirubin levels of persons homozygous or even het

122 trong replication for a genetic influence on serum bilirubin levels of the UGT1A1 locus (P < 5 x 10(-

123 tabase (the Health Improvement Network) with serum bilirubin levels recorded but no evidence of hepat

124 aused human BUGT1 expression again, reducing serum bilirubin levels to those observed after the first

125 In conclusion, serum bilirubin levels vary significantly with gender, r

126 vels were elevated in some LEC rats, whereas serum bilirubin levels were normal.

127 ing antibodies and a CTL response, and their serum bilirubin levels were not reduced following subseq

128 was detectable in liver for 2 days only, and serum bilirubin levels were not reduced.

129 In control rats serum bilirubin levels were reduced for only 4 wk, and v

130 Serum bilirubin levels were significantly decreased by 3

131 /- mice than in wild-type CBDL mice, whereas serum bilirubin levels were the same, suggesting that Mr

132 We examined the association of serum bilirubin levels with nonrelapse mortality by day

133 approximately 1.0% of the variation in total serum bilirubin levels, respectively.

134 s but exhibited higher hepatic bile acid and serum bilirubin levels, suggesting defects in bile expor

135 in the UDPGT family directly associated with serum bilirubin levels, which is in turn implicated with

136 e, white blood cell, and platelet counts and serum bilirubin levels.

137 ndrome (veno-occlusive disease) and by total serum bilirubin levels.

138 ion period, and associated with reduction of serum bilirubin levels.

139 unal transplants from Wistar rats normalizes serum bilirubin levels.

140 al Wistar rats lowered but did not normalize serum bilirubin levels.

141 ilirubin glucuronides and a 70% reduction of serum bilirubin levels.

142 n of UGT1A1 in the small intestine to reduce serum bilirubin levels.

143 ile was done in all the patients with normal serum bilirubin levels.

144 ion and predisposes the infant to high total serum bilirubin levels.

145 ic toxicity, as well as baseline and maximal serum bilirubin levels.

146 phenobarbital has been used for reducing the serum bilirubin load.

147 ancer compared with those with CCA had lower serum bilirubin, lower carbohydrate antigen 19-9 (CA 19-

148 bove 50%), and have adequate organ function (serum bilirubin </=3.0 mg/dL and serum creatinine </=3.0

149 n peak, 510 U/L; range, 286 to 770 U/L), and serum bilirubin (mean peak, 160.7 micromol/L [9.4 mg/dL]

150 r transplantation, alanine aminotransferase, serum bilirubin, necrosis, and apoptosis all increased.

151 associated with poor prognosis were baseline serum bilirubin, no reversibility of type-1 HRS, lack of

152 bility of type-1 HRS were age, high baseline serum bilirubin, nosocomial infection, and reduction in

153 Transient elevations in serum bilirubin occurred in all treatment groups.

154 /dl, 95% CI 1.1 to 1.4), pretransplant total serum bilirubin (odds ratio 1.4 for each 10-mg/dl increa

155 ortic balloon counterpulsation, preoperative serum bilirubin of >1.0 mg/dL, blood transfusion require

156 l steroid treatment was defined as a drop in serum bilirubin of <25% within 7 days or death within 6

157 h was defined as a rate of increase in total serum bilirubin of less than 0.2 mg per deciliter per ho

158 ons (grade >/= 3b) after stage 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4),

159 ), ascites (p = 0.030, OR = 1.212), elevated serum bilirubin (p = 0.007, OR = 4.357) and large tumour

160 r >5 cm (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517) predicted AHD.

161 On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0

162 preoperative serum creatinine (P=0.001) and serum bilirubin (P=0.02) levels were associated with a h

163 Total serum bilirubin, percent weight gain, and serum creatini

164 Mean total serum bilirubin plummeted from 8.41 +/- 0.20 to 0.76 +/-

165 ation of serum albumin, and concentration of serum bilirubin predict the risk of complications and de

166 y of liver disease, grade of encephalopathy, serum bilirubin, prothrombin time, creatinine, serum pho

167 0.16), while FEV1% was positively related to serum bilirubin (r = 0.15).

168 , serum creatinine (relative risk, 3.8), and serum bilirubin (relative risk, 3.7) were found to be in

169 ch is evident from a significant decrease in serum bilirubin, reticulocyte counts, and serum erythrop

170 station at 12 facilities that used universal serum bilirubin screening before (January 1, 2010, throu

171 s of our nontransplanted patients identified serum bilirubin, serum albumin, blood urea, ascites, and

172 ter birth that lead to the rapid increase in serum bilirubin, the events that control delayed express

173 s, encephalopathy, or varices; a doubling of serum bilirubin to 2.5 mg/dL or greater; a fall in serum

174 onstrated significant evidence of linkage of serum bilirubin to chromosome 2q, with a LOD score of 3.

175 ) mice, which exhibit severe levels of total serum bilirubin (TSB) because of a developmental delay i

176 hildren exposed to excessive levels of total serum bilirubin (TSB) during the neonatal period.

177 usion is recommended for newborns with total serum bilirubin (TSB) levels thought to place them at ri

178 Total serum bilirubin (TSB) levels were examined at 48 hours p

179 tal jaundice are based on age-specific total serum bilirubin (TSB) levels.

180 Total serum bilirubin values up to day +100, death, or relapse

181 ients treated with twice-daily HDAC when the serum bilirubin was > or = 2.0 mg/dL compared with twice

182 a median follow-up of 15.8 months, baseline serum bilirubin was not predictive of 1-year survival (4

183 A clinically significant reduction in serum bilirubin was observed with a dose as low as 6 x 1

184 Serum bilirubin was of no prognostic value in ALF, and N

185 With histidine containing FPL, serum bilirubin was reduced by 40% +/- 5%, and bilirubin

186 ng negative association between CVD-risk and serum bilirubin we further explored potential associatio

187 trolox equivalent antioxidant capacity, and serum bilirubin, which may protect against lipid peroxid

188 e after Kasai portoenterostomy and will have serum bilirubin within the normal range within 6 months.